Efficacy and Safety of Org 25969 Administered After Zemuron® (MK-8616-042)

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 1, 2004

Primary Completion Date

May 26, 2005

Study Completion Date

May 26, 2005

Conditions
Neuromuscular Blockade
Interventions
DRUG

MK-8616

MK-8616 will be administered at doses of 0.5, 1.0, 2.0, 4.0 and 8.0 mg/kg iv as a 30-second infusion. Doses are based on actual body weight.

DRUG

Zemuron®

Zemuron® (0.6 or 1.2 mg/kg, iv) will be administered as a 10-second bolus infusion to achieve 1 to 2 PTCs. If needed, a maintenance dose of 0.15 mg/kg will be given. Doses are based on actual body weight.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03519867 - Efficacy and Safety of Org 25969 Administered After Zemuron® (MK-8616-042) | Biotech Hunter | Biotech Hunter